
Esomeprazole sodium
CAS No. 161796-78-7
Esomeprazole sodium( S)-Omeprazole sodium )
Catalog No. M12368 CAS No. 161796-78-7
A proton pump inhibitor that reduces stomach acid secretion by inhibition of the H+/K+-ATPase in the parietal cells.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 37 | In Stock |
![]() ![]() |
10MG | 55 | In Stock |
![]() ![]() |
25MG | 87 | In Stock |
![]() ![]() |
50MG | 113 | In Stock |
![]() ![]() |
100MG | 146 | In Stock |
![]() ![]() |
200MG | Get Quote | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameEsomeprazole sodium
-
NoteResearch use only, not for human use.
-
Brief DescriptionA proton pump inhibitor that reduces stomach acid secretion by inhibition of the H+/K+-ATPase in the parietal cells.
-
DescriptionA proton pump inhibitor that reduces stomach acid secretion by inhibition of the H+/K+-ATPase in the parietal cells; the (S)-(?)-enantiomer of omeprazole for treatment of dyspepsia, peptic ulcer disease, and gastroesophageal reflux disease.Ulcer Approved(In Vitro):Esomeprazole (25-100 μM; 20 hours; MDA-MB-468 cells) treatment suppresses growth of triple-negative breast cancer cell in vitro in a dose-dependent manner through increase in their intracellular acidification.(In Vivo):Esomeprazole (30-300 mg/kg; oral gavage; daily; for 19 or 11 days; C57BL/6J mice) treatment significantly inhibits the progression of fibrosis throughout the lungs of the animals. Esomeprazole also reduces circulating markers of inflammation and fibrosis.
-
In VitroEsomeprazole (25-100 μM; 20 hours; MDA-MB-468 cells) treatment suppresses growth of triple-negative breast cancer cell in vitro in a dose-dependent manner through increase in their intracellular acidification. Cell Viability AssayCell Line:MDA-MB-468 cellsConcentration:25 μM, 50 μM, 75 μM, 100 μM Incubation Time:20 hours Result:Suppressed growth of triple-negative breast cancer cell in vitro in a dose-dependent manner.
-
In VivoEsomeprazole (30-300 mg/kg; oral gavage; daily; for 19 or 11 days; C57BL/6J mice) treatment significantly inhibits the progression of fibrosis throughout the lungs of the animals. Esomeprazole also reduces circulating markers of inflammation and fibrosis. Animal Model:C57BL/6J mice (8-weeks old, 25-30 g) treated with cotton smoke-induced lung injury Dosage:30 mg/kg, 300 mg/kg Administration:Oral gavage; daily; for 19 or 11 days Result: Significantly inhibited the progression of fibrosis throughout the lungs of the animals.
-
SynonymsS)-Omeprazole sodium
-
PathwayMembrane Transporter/Ion Channel
-
TargetProton Pump
-
RecptorH+/K+-ATPase
-
Research AreaOther Indications
-
IndicationUlcer
Chemical Information
-
CAS Number161796-78-7
-
Formula Weight367.3979
-
Molecular FormulaC17H18N3NaO3S
-
Purity>98% (HPLC)
-
Solubility10 mM in H2O
-
SMILESCC1=CN=C(C(=C1OC)C)C[S@](=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+]
-
Chemical Name1H-Benzimidazole, 6-methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-, sodium salt (1:1)
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog



related products
-
CS-526
CS-526 (AKU 517;R 105266) is a potent, competitive, and reversible acid pump antagonist (potassium-competitive acid blocker) that inhibits H+,K+-ATPase activity with IC50 of 61 nM.
-
Tegoprazan
A novel potent, highly selective, competitive and orally active inhibitor of gastric H+/K+-ATPase with IC50 of ranging 0.29-0.52 uM porcine, canine and human H+/K+-ATPases in vitro.
-
AZD-0865
A potent, selective acid pump antagonist (potassium-competitive acid blocker or P-CAB) that reversiblely inhibits gastric H+/K+-ATPase with pIC50 of 6.5.